Detalhe da pesquisa
1.
Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis.
Rheumatology (Oxford)
; 2023 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37947318
2.
Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review.
Health Qual Life Outcomes
; 19(1): 94, 2021 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33736649
3.
The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland.
J Med Econ
; 27(1): 682-696, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38650583
4.
Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis.
Rheumatol Ther
; 2024 Jun 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38916823
5.
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies.
RMD Open
; 10(2)2024 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38834351
6.
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2.
RMD Open
; 10(2)2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38599650
7.
Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis.
RMD Open
; 9(4)2023 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38035757
8.
Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews.
J Patient Rep Outcomes
; 5(1): 128, 2021 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34894307
9.
A modelling approach to estimate the prevalence of treatment-resistant schizophrenia in the United States.
PLoS One
; 15(6): e0234121, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32497106